High Dose Interleukin-2 Followed by Intermittent Low Dose Temozolomide in Patients With Melanoma

NCT01124734 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

17

Enrollment

OTHER

Sponsor class

Conditions

Malignant Melanoma

Interventions

DRUG: Interleukin-2
DRUG: Temozolomide

Sponsor

Milton S. Hershey Medical Center